Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $55.57M
• Dividend Yield: N/A
• Average Volume (3M): 106.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.89
• Revenue Growth: 69.65%
• EPS Growth: 27.98%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 47,903,214
• 10 Day Avg. Volume: 101,538
• 30 Day Avg. Volume: 106,053
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.92
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.09
• Enterprise Value/Gross Profit: -385.07
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $4.00
• Price Target Upside: 244.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 49 Neutral
• Price Target: $1.00 ▼(-13.79%Downside)

The stock score is significantly impacted by poor financial performance due to declining revenues and negative profitability. While technical indicators suggest some potential for price improvement, the valuation remains weak with a negative P/E ratio. The absence of dividends further emphasizes the company's focus on overcoming financial challenges.

Positive Factors

Clinical Trials

SL-325's DR3 receptor blockade is expected to provide more durable protection from inflammation than targeting the TL1A ligand, which could more effectively neutralize the signaling axis in IBD.

Financial Performance

The announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).

Research and Development

Positive preclinical data for SL-325 was presented at the 20th Congress of ECCO in Inflammatory Bowel Diseases, highlighting its potential as a differentiated approach to current IBD treatments.

Negative Factors

Expenses

Shattuck released its Q1 financials. These included R&D expenses of $9.9MM (vs our $9MME) and SG&A expenses of $4.5MM (vs our $4MME). This led to Q1 net losses of $13.7MM.

Pipeline Progress

The early stage of the company pipeline and a lack of near-term value drivers lead to maintaining a Hold Rating for Shattuck.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

How the Company Makes Money

Shattuck Labs generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve the co-development and commercialization of its proprietary ARC platform-based therapies. Additionally, the company may earn revenue from milestone payments and royalties associated with the successful advancement and commercialization of its therapeutic candidates. As a clinical-stage company, Shattuck Labs may also receive funding from grants or research collaborations to support its research and development activities.

Shattuck Labs Financial Statement Overview

Summary

Shattuck Labs faces significant financial challenges with declining revenues, negative profitability, and operational inefficiencies. Despite a strong cash position, the company relies heavily on external financing, typical in the biotechnology sector due to high R&D costs.

Income Statement

The company shows a significant decline in revenue growth over the years, with TTM revenue at $19.1 million compared to $30 million in 2021. Gross profit margin is negative, indicating high operating costs. Net profit margin remains negative, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and a lack of profitability.

Balance Sheet

The debt-to-equity ratio is low due to minimal debt, which is a positive aspect. However, the equity ratio has decreased over time, indicating a decline in financial stability. Return on equity is negative, reflecting persistent losses. The company maintains a strong cash position, although total assets have decreased, indicating potential liquidity concerns.

Cash Flow

The operating cash flow to net income ratio is negative, reflecting cash outflows from operations. Free cash flow has improved slightly but remains negative, indicating an inability to generate sufficient cash to cover expenses. Positive financing cash flow suggests reliance on external funding to support operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
19.10M	5.72M	1.66M	652.00K	30.02M	9.93M
	Gross Profit
-141.00K	5.72M	-2.38M	-2.72M	28.64M	-27.55M
	EBIT
-74.91M	-80.57M	-91.96M	-103.33M	-45.27M	-36.93M
	EBITDA
-71.12M	-76.74M	-87.92M	-100.26M	-43.89M	-36.31M
	Net Income Common Stockholders
-70.61M	-75.41M	-87.30M	-101.94M	-44.35M	-35.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
60.90M	72.99M	130.63M	161.28M	268.80M	335.45M
	Total Assets
77.17M	91.05M	159.56M	205.32M	298.58M	348.99M
	Total Debt
2.27M	3.41M	4.20M	4.20M	0.00	0.00
	Net Debt
-58.63M	-53.98M	-121.42M	-43.18M	-92.27M	-157.90M
	Total Liabilities
9.58M	11.42M	14.86M	29.17M	26.80M	39.13M
	Stockholders Equity
67.59M	79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow		Free Cash Flow
-56.45M	-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
	Operating Cash Flow
-56.39M	-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
	Investing Cash Flow
40.37M	-8.51M	110.86M	49.44M	-10.44M	-146.32M
	Financing Cash Flow
914.00K	787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Neutral. The current price of 1.16 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 0.97, and below the 200-day MA of 1.48, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 66.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$425.37M	5.69	-58.97%	―	23.81%	146.45%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
DTIL	53 Neutral	$57.66M	2.40	-50.81%	―	-11.11%	79.74%
KRON	51 Neutral	$54.26M	―	-59.49%	―	21.15%	46.44%
STTK	49 Neutral	$55.57M	―	-71.90%	―	69.65%	27.98%
GANX	46 Neutral	$56.60M	―	-290.21%	―	-100.00%	44.28%
PEPG	40 Underperform	$49.08M	―	-75.45%	―	―	14.06%